The level of human natural antibodies of immunoglobulin M isotype against Le^C in patients with breast cancer is lower than in healthy women. The epitope specificity of these antibodies has been characterized using a printed glycan array and enzyme-linked immunosorbent assay (ELISA), the antibodies being isolated from donors’ blood using Le^C-Sepharose (Le^C is Galβ1-3GlcNAcβ). The isolated antibodies recognize the disaccharide but do not bind to glycans terminated with Le^C, which implies the impossibility of binding to regular glycoproteins of non-malignant cells. The avidity (as dissociation constant value) of antibodies probed with a multivalent disaccharide is 10⁻⁹ M; the nanomolar level indicates that the concentration is sufficient for physiological binding to the cognate antigen. Testing of several breast cancer cell lines showed the strongest binding to ZR 75-1. Interestingly, only 7% of the cells were positive in a monolayer with a low density, increasing up to 96% at highest density. The enhanced interaction (instead of the expected inhibition) of antibodies with ZR 75-1 cells in the presence of Galβ1-3GlcNAcβ disaccharide, indicates that the target epitope of anti-Le^C antibodies is a molecular pattern with a carbohydrate constituent rather than a glycan.

The mother and fetus incompatibility due to Rh-factor, blood group or other blood factors can lead to hemolytic disease of the fetus and newborn (HDN). HDN is a clinical disease condition of the fetus and newborn as a result of hemolysis, when maternal IgG alloantibodies cross the placenta and destroy the red blood cells of the fetus and newborn. The child disease begins in utero and can dramatically increase immediately after birth. As a result, hyperbilirubinemia and anemia develop, that can lead to abortions, serious complications, or death of the neonates in the absence of proper therapy. The range of HDN has changed significantly now compared to previous decades. Half a century ago, HDN was considered an almost complete synonym of RhD-alloimmunization, and this was a frequent problem for newborns. By now due to the high effective of Rh-conflict prevention, immunological AB0-conflicts have become the most common cause of HDN. The review aimes to one of the main causes of jaundice and anemia in neonates at present, i.e. HDN due to immunological AB0-conflict of mother and newborn (AB0-HDN). The main participants of the AВ0- incompatibility mother and child are considered, namely A- and B-glycans, as well as the corresponding anti-glycan alloantibodies. Close attention is paid to the structure features of glycan alloantigens on the red blood cells of the fetus and adult. The possible correlation of the frequency and severity of HDN with the blood group of mother and child, as well as with the titer of maternal alloantibodies, has been considered. The influence of immunoglobulin G subclasses on the AB0-HDN development has been evaluated. In most cases, AB0-HDN appear when the mother has the blood group 0, and the fetus has the group A (subgroup A1) or the group B. Other rare incidences of AB0-incompatibility with severe course are occurred. As a whole the etiology of AB0-HDN is complex and the HDN severity is influenced by many factors. The authors have analyzed statistical data, as well as the prevalence of AB0-incompatibility and AB0-HDN in various regions of the world. Current approaches to the diagnosis of AB0-HDN are discussed in addition. By now the problems of AB0- HDN occurrence and developing of ways to overcome this disease remain relevant.

Background. Naturally occurring human antibodies against glycans recognize and quickly eliminate infectious bacteria, viruses and aberrantly glycosylated neoplastic malignant cells, and they often initiate processes that involve the complement system. Methods. Using a printed glycan array (PGA) containing 605 glycoligands (oligo- and polysaccharides, glycopeptides), we examined which of the glycan-binding antibodies are able to activate the complement system. Using this PGA, the specificities of antibodies of the IgM and IgG classes were determined in the blood serum of healthy donors (suggested as mostly natural), and, then, using the same array, it was determined which types of the bound immunoglobulins were also showing C3 deposition. Results. It was found that about 30% of anti-glycan antibodies in human serum detected by the PGA did not activate the complement. They were mostly IgGs and directed to bacterial O-antigens; no apparent common structural motif within their target polysaccharides was found. Antibodies to blood group systems ABO and Forssman, xeno-antigens, a number of polysaccharides from various strains of S. enterica, E. coli and P. alcalifaciens, as well as small fragments of bacterial polysaccharides were recognized by complement-activating antibodies as expected. A complement-activating antibody was affinity-isolated on glycan-Sepharose from human serum, and, in the presence of the complement, it lysed red blood cells coated with the same glycan (kodecytes, where glycans expressed on biological membranes), while an isolated complement non-activating antibody did not, which confirms the validity of the solid-phase PGA results. Conclusions. Thus, ~30% of human anti-glycan antibodies lack the ability to activate the complement system. The function of the widely represented immunoglobulins that do not cause C3 deposition remains unclear.

Selective insertion of lipid probes from the external milieu into raft regions of the cell membrane would enable targeted studies of raft molecular organization and of raft-associated peptide and glycan components. In this work, we compared the insertion of several synthetic glycolipids into raft and non-raft membrane areas of Raji and EA.hy 926 endothelial cells. A glyco-cholesterol derivative in which the 3β oxygen atom is replaced by NH was selected as a candidate raft-selective probe. Although this glycolipid also inserted into other membrane areas, its raft-to-non-raft distribution ratio was higher than that of its O-analog (natural 3β-O-cholesterol).

Background: The clinically significant antibody anti‐A,B together with anti‐A and anti‐B has been known for many decades to be present in blood group O plasma. As anti‐A,B is only reactive when an A or B antigen is present, its contribution to titer cannot be easily distinguished from anti‐A and/or anti‐B. Study Design and Methods: Chemically synthesized AB epitope (ABep) was attached onto red cells creating ABep‐kodecytes; methodology was optimized and then used together with group A‐ and B‐kodecytes to semi‐quantitative undiluted plasma samples of all ABO blood groups for anti‐A, anti‐B, and anti‐A,B. Standard titers with plasma dilutions against natural A ₁ and B cells were performed in parallel. Results: ABep20‐kodecytes were able to semi‐quantitate anti‐A,B independently of anti‐A and anti‐B. Anti‐A and anti‐B levels were also able to be inferred by deduction of the anti‐A,B contribution. There was a large range in the levels of anti‐A,B in the group O samples, including in those determined to have high‐titer ABO antibodies. Unexpectedly, some group A, B, and AB individuals were also found to have an anti‐A,B‐like antibody. Discussion: Anti‐A,B is a much more complex antibody than current understanding, and shows a range of activity over a large continuum, which includes in vitro detectable anti‐A,B‐like antibodies in non‐group O samples. The ability to measure anti‐A,B independently of anti‐A and anti‐B levels may be useful in evaluating clinical associations.